Targets › PEDF
1 program from 1 company in 1 trial: 1 Phase 2; Ophthalmology; next expected readout Feb 2028.
Neurotrophic protein; induces extensive neuronal differentiation in retinoblastoma cells. Potent inhibitor of angiogenesis. (UniProt, P36955)
Open in Phaseline: the race on PEDF, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| NexThera | NT-101 ophthalmic solution Pigment epithelium-derived factor (PEDF) in type I atelocollagen formulation | PEDF | Phase 2 | Wet Age Related Macular Degeneration | Feb 2028 |
Wet Age Related Macular Degeneration (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.